Skip to main content

iPSC-based Biotech Firm Orig3N Raises $3.1M

NEW YORK (GenomeWeb) – Orig3N, a biotechnology firm developing a disease-modeling platform targeting rare genetically inherited diseases, today announced it raised $3.1 million in a private round of financing. 

The proceeds will go toward expanding Boston-based Orig3N's Life Capsule, a bio-repository for people to contribute their cells via a blood sample. The cells are reprogrammed into induced pluripotent stem cells, which can be used for disease modeling outside the body for medical research, as well as for individualized therapy. 

Participants in the financing included Hatteras Venture Partners, Harris & Harris Group, KTB, and Mountain Group Capital. 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.